Moffitt logo

Clinical Trials Search

Search Results:

Showing of 50

CLINICAL TRIAL 18569

A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 18933

Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19127

A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed by Nivolumab Monotherapy

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Cancer Type: Neurologic Oncology

View Trial Details

CLINICAL TRIAL 19634

Study of Resistance Mechanisms to Checkpoint Blockade

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19407

An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage IIIB/C Melanoma Patients

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 18989

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19754

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19691

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study (Keynote 716)

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19703

A Phase 1, Open-Label, Dose Finding Study of ASN007 in Patients with Advanced Solid Tumors

Cancer Type: Multiple

View Trial Details

CLINICAL TRIAL 19109

A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Cancer Type: Genitourinary

View Trial Details

CLINICAL TRIAL 18874

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 18309

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 18992

A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19706

A Phase II Biomarker Trial of Avadomide (CC-122) in Combination with Nivolumab in Advanced Melanoma

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19733

Motivating a Spectrum of Cancer Patients to Quit Smoking: Intervention Development and Feasibility

Cancer Type: Multiple

View Trial Details

CLINICAL TRIAL 19777

A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19958

Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only).

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19228

A Phase 2, Multi-Center, Open Label Study of NIR178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin lymphoma

Cancer Type: Thoracic

View Trial Details

CLINICAL TRIAL 19491

The IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity

Cancer Type: Multiple

View Trial Details

CLINICAL TRIAL 19601

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Cancer Type: Cutaneous

View Trial Details

CLINICAL TRIAL 19686

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Cancer Type: Cutaneous

View Trial Details